CD5 and B-cell chronic lymphocytic leukemia: To explore the effectiveness of PNA treatment, we chose to use the human T-leukemia Jurkat cell line due to its high and more stable expression of CD5 compared to the few commercially available B-CLL cell lines [35, 36].